IMM 1.28% 39.5¢ immutep limited

Lag-3 Research Operative, page-24

  1. 91 Posts.
    lightbulb Created with Sketch. 179
    Stories of commitment, contribution and appreciation such as Ahjay's in Immutep are built on belief.

    Belief in the work, toil and example of our Company Leaders.

    BIOGRAPHY
    :
    Frédéric Triebel (born 20 November 1954) is a French immunologist who is best known for his 1990 discovery of the LAG3 immune control mechanism. Triebel worked through the 1990s in a collaboration between Institut Gustave Roussy and Merck Serono to establish LAG-3's mechanism of action in T cells and dendritic cells. In 2001 he founded Immutep SA, a biotech company, to develop the therapeutic potential of LAG3. In 2014 this company was acquired by Prima BioMed, where Triebel remains Chief Scientific and Medical Officer.

    Early life and education:

    He completed his Doctor of Medicine degree at Poitiers University in 1981 and then a four-year clinical hematology fellowship in Paris hospitals. In 1983, Frédéric Triebel received the Gold Medal of the Paris Medicine University. In parallel, Triebel gained a PhD in Immunology at the University of Paris VI in 1985. His PhD thesis was in the field of immunogenetics, focused on the mechanisms that activate human antigen-specific T-cells.

    Career:

    From 1986 until the late 1990s, Triebel headed the cellular immunology group in the Department of Clinical Biology of the Institut Gustave Roussy. In 1990 he gained a Chair in Molecular Immunogenetics and Biotherapy at the University of Paris XI. Between 1991 and 1996 was director of an INSERM unit (U333). He founded Immutep SA in 2001 in order to develop the clinical potential of LAG3 and stayed with this company through to its acquisition by Prima BioMed in 2014. Triebel remains Chief Scientific and Medical Officer of Immutep.

    To read more of the above biography go to:

    Peoplepill Biography - Dr Triebel

    IMO
    The resilience and belief of Dr Triebel to remain focused for over 30 years and deliver this groundbreaking science to patients that need help is a champions effort. As shareholders we should all forget the stock price for a moment & consider 30 PLUS YEARS IN THE LAB!!!

    My reaction is to be upstanding and vigorously applaud this incredible man, what a enormous sacrifice & contribution he has made to medical science and the good of humanity.

    Good luck to ALL holders.

    IMO
    DYOR

 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
39.5¢
Change
0.005(1.28%)
Mkt cap ! $573.7M
Open High Low Value Volume
38.5¢ 40.0¢ 38.5¢ $612.4K 1.563M

Buyers (Bids)

No. Vol. Price($)
31 170586 39.0¢
 

Sellers (Offers)

Price($) Vol. No.
39.5¢ 87190 22
View Market Depth
Last trade - 13.51pm 05/09/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.